The Claim
Decaffeinated coffee is not associated with a reduced risk of Alzheimer’s disease, Parkinson’s disease, or neurodegenerative mortality, indicating that caffeine may be necessary for the neuroprotective effects attributed to coffee.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People who drink decaffeinated coffee do not have a lower risk of Alzheimer’s disease, Parkinson’s disease, or death from neurodegenerative causes compared to those who do not drink it, suggesting that caffeine in regular coffee may be responsible for any protective effects.
See the scientific wording
Decaffeinated coffee shows no significant association with reduced risk of Alzheimer’s disease, Parkinson’s disease, or neurodegenerative mortality, suggesting caffeine may be a key component in the observed neuroprotective effects of coffee.
Caffeine stops a brain chemical called adenosine from binding to its receptors, which prevents inflammation in brain cells and keeps neurons working properly. Without caffeine, this protection does not happen, and brain cells become more likely to break down over time.
What the research says
1 studyPeople who drank coffee with caffeine had a lower risk of Alzheimer’s and Parkinson’s, but those who drank decaf didn’t get the same benefit — suggesting caffeine is what’s helping.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.